Hypoparathyroidism Treatment Market Poised to Register at CAGR of 8.0% by 2026: Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sun Pharmaceutical Industries
The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the global hypoparathyroidism treatment market is still in its infancy, with most of...
View full press release